4//SEC Filing
Meyer Andrew Hollman 4
Accession 0001864159-25-000006
CIK 0001817713other
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 8:00 PM ET
Size
10.8 KB
Accession
0001864159-25-000006
Insider Transaction Report
Form 4
Meyer Andrew Hollman
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-01$10.59/sh+3,333$35,296→ 88,307 total - Sale
Common Stock
2025-12-01$32.85/sh−2,700$88,708→ 85,607 total - Sale
Common Stock
2025-12-01$33.52/sh−633$21,221→ 84,974 total - Exercise/Conversion
Stock Option (right to buy)
2025-12-01−3,333→ 114,768 totalExercise: $10.59Exp: 2031-05-13→ Common Stock (3,333 underlying)
Footnotes (4)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.
- [F2]The weighted average sale price for the transaction reported was $32.8548 and the range of prices were between $32.27 and $33.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The weighted average sale price for the transaction reported was $33.5247 and the range of prices were between $33.28 and $33.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]Immediately exercisable.
Documents
Issuer
Janux Therapeutics, Inc.
CIK 0001817713
Entity typeother
Related Parties
1- filerCIK 0001864159
Filing Metadata
- Form type
- 4
- Filed
- Dec 2, 7:00 PM ET
- Accepted
- Dec 3, 8:00 PM ET
- Size
- 10.8 KB